SYNERGY(SZ:300636)2023-04-23 16:00Financial Performance - The company's operating revenue for 2022 was CNY 719,908,426.87, representing a 21.58% increase compared to CNY 592,126,648.93 in 2021[24]. - The net profit attributable to shareholders for 2022 was CNY 100,667,359.97, up 24.10% from CNY 81,119,813.17 in 2021[24]. - The cash flow from operating activities increased by 49.23% to CNY 195,996,737.04 in 2022, compared to CNY 131,338,816.17 in 2021[24]. - The total assets at the end of 2022 reached CNY 2,258,855,478.13, an 18.47% increase from CNY 1,906,727,705.65 at the end of 2021[24]. - The net assets attributable to shareholders increased by 48.59% to CNY 1,319,668,598.10 at the end of 2022, compared to CNY 888,112,993.37 at the end of 2021[24]. - The basic earnings per share for 2022 were CNY 0.3084, a 17.40% increase from CNY 0.2627 in 2021[24]. - The company reported a total of CNY 3,271,050.26 in non-recurring gains and losses for 2022, compared to CNY 1,929,871.51 in 2021[30]. - The company achieved a sales revenue of 719.91 million yuan, a year-on-year increase of 21.58%[67]. - The external sales reached 583.91 million yuan, with a growth of 26.79% compared to the previous year[67]. - The net profit for the period was 100.67 million yuan, representing a 24.10% increase from the previous year[67]. - The company reported a total revenue of 1.5 billion for the year 2022, representing a year-on-year growth of 15%[134]. - The company reported a total revenue of 1,644 million in 2022, with a year-on-year increase of 4.823%[159]. - The net profit for the year was 74.21 million, reflecting a growth of 25.04% compared to the previous year[159]. Research and Development - The average R&D investment over the past three years has been 7.74% of sales, indicating a strong focus on innovation and technology development[39]. - The company has established several technology innovation platforms, including the Jiangxi Provincial Engineering Research Center for Specialty Raw Materials, enhancing its R&D capabilities[39]. - The company has completed bioequivalence (BE) for 13 downstream products, including drugs like Venlafaxine and Celecoxib[45]. - The R&D investment amounted to 60.91 million yuan, accounting for 8.46% of the current operating revenue[67]. - The company has a research and development team of over 400 personnel, ensuring efficient selection and rapid market introduction of products with broad market prospects[57]. - The R&D department has successfully filed for 12 new patents, with 8 already granted, indicating a strong focus on innovation[168]. - The company is investing 50 million RMB in new technology to improve production efficiency, targeting a 15% reduction in operational costs[168]. - The company plans to increase R&D investment to improve innovation capabilities and strengthen the CDMO team's capacity for new drug projects[123]. Market Expansion and Strategy - The company is actively pursuing market expansion and new product development to enhance its competitive position in the pharmaceutical sector[4]. - The company has seen a significant increase in demand for its products due to the rising health awareness among the Chinese population[34]. - The company is gradually expanding its contract processing services for original drug manufacturers, in addition to supplying raw materials for generic drug companies[34]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[129]. - Market expansion plans include entering two new provinces, which are projected to increase market share by 5%[127]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 300 million CNY earmarked for potential targets[127]. - The company aims to strengthen brand building and contract manufacturing while focusing on the chemical pharmaceutical industry to enhance its market position[111]. - The company plans to enter two new international markets by the end of 2023[137]. Compliance and Risk Management - The company faces risks related to national policies and industry competition due to ongoing healthcare reforms and regulatory changes[3]. - The company has implemented measures to ensure compliance with environmental standards, but increasing costs for waste management are anticipated due to stricter regulations[5]. - The company has not experienced any major safety incidents to date, but acknowledges potential risks associated with handling hazardous materials in production[5]. - The company’s product quality is subject to high standards, and any quality issues could adversely affect its reputation and operational performance[6]. - The company maintains independence from its controlling shareholders in terms of business, assets, personnel, and finance, with a complete and independent operational system[153]. Employee and Management - The total number of employees at the end of the reporting period is 1,280, with 1,256 from the parent company and 24 from major subsidiaries[181]. - The company has implemented an employee stock incentive plan, with a total of 30.72 million shares allocated for this purpose[159]. - The company has a comprehensive compensation policy that includes competitive salaries, benefits, and performance-based bonuses to motivate employees[182]. - The company aims to enhance its training management system and collaborate with external training institutions to develop employees' potential and management talent[184]. - The company has established a performance evaluation system that links assessment results to compensation, promoting a performance-oriented culture[182]. Environmental Commitment - The company has implemented measures to ensure compliance with environmental standards, but increasing costs for waste management are anticipated due to stricter regulations[5]. - The company's wastewater treatment capacity is 1,500 tons/day and air treatment capacity is 30,000 cubic meters/hour at one facility, showcasing its commitment to environmental standards[38]. - The company has a strong production capacity with over 600 reaction vessels and a total volume exceeding 3 million liters, positioning it competitively in the global market[66]. - The management team emphasized a commitment to sustainability, with plans to reduce carbon emissions by 25% over the next five years[168]. Shareholder Engagement - The company emphasizes the importance of accurate and timely information disclosure, with the chairman as the primary responsible person for information disclosure[150]. - The company has established various channels for investor communication, including dedicated phone lines and email[150]. - The participation rate of investors in the 2022 first extraordinary general meeting was 46.71%[156]. - The company respects and protects the legitimate rights and interests of stakeholders, emphasizing social responsibility and communication[152].